Autobio Diagnostics Co., Ltd. (SHA:603658)

Market Cap	24.78B
Revenue (ttm)	4.58B
Net Income (ttm)	1.27B
Shares Out	572.12M
EPS (ttm)	2.20
PE Ratio	19.68
Forward PE	16.17
Dividend	1.05 (2.43%)
Ex-Dividend Date	Jun 5, 2024

Volume	4,583,820
Average Volume	3,530,518
Open	43.60
Previous Close	43.56
Day's Range	43.06 - 44.44
52-Week Range	37.56 - 66.36
Beta	0.06
RSI	59.61
Earnings Date	Apr 18, 2025

About Autobio Diagnostics

Autobio Diagnostics Co., Ltd. engages in the research and development, production, marketing, sale, and service of clinical diagnostic products in China and internationally. The company offers immunoassay, biochemistry, and microbiology products; reagents and instruments; and technical and support, and training services, as well as engages in biology research and development activities. Its immunoassay products consist of AutoLumo S900 and AutoLumo A1860 that provides user experience for small and medium size labs; AutoLumo A6200/A6600, an auto...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1998
• Employees: 5,539
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603658

Financial Performance

In 2023, Autobio Diagnostics's revenue was 4.44 billion, an increase of 0.05% compared to the previous year's 4.44 billion. Earnings were 1.22 billion, an increase of 4.28%.